Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
Side-by-side · Research reference

Thymosin α-1vsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3Reviewed8/39 cited
BFDA-ApprovedVerified14/45 cited
Thymosin α-1
Immune modulator · Approved (some countries)
1.6 mgPer doseIyer 2007
Phase 3Evidence levelIyer 2007Camerini 2001
~2 hrHalf-life
SQ · 2× weekly · 6+ months for chronic indications
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023
20.9%Body-weight ↓Jastreboff 2022
~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023
SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter
Thymosin α-1
Tirzepatide
Primary target
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—

02Dosage Protocols

Parameter
Thymosin α-1
Tirzepatide
Standard dose (HBV/HCV)
1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007
—
Frequency
2× weekly (Mon/Thu typical)
—
Lower / starter dose
0.8 mg per injection
—
Evidence basis
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
6–12 months for chronic indications
Indefinite for chronic indication
Reconstitution
Sterile water for injection per vial label
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
Timing
No specific time
Once weekly, any time of day
Half-life
~2 hours plasma; tissue effect days
~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023
Standard dose (T2D)
—
5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.

04Side Effects & Safety

Parameter
Thymosin α-1
Tirzepatide
Injection site reaction
Erythema, mild discomfort
Mild erythema, pruritus
GI symptoms
Rare nausea
Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022
Fatigue
Common during initial weeks
—
Fever / flu-like
Mild interferon-like response possible
—
Autoimmune
Theoretical risk; caution in active autoimmune disease
—
Cancer risk
No signal — used as adjuvant in oncology
—
Pregnancy / OB
Avoid
Contraindicated
Pancreatitis risk
—
Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Thymosin α-1
  • ·Pregnancy / breastfeeding
  • ·Hypersensitivity to peptide
  • ·Concurrent immunosuppressant therapy (transplant patients)
Tirzepatide
  • ·MTC personal or family history; MEN2
  • ·Pregnancy / breastfeeding
  • ·Hypersensitivity to tirzepatide
Relative Contraindications
Thymosin α-1
  • ·Active autoimmune disease
  • ·Severe immunocompromised state without supervision
Tirzepatide
  • ·Severe gastroparesis
  • ·History of pancreatitis
  • ·Diabetic retinopathy

05Administration Protocol

Parameter
Thymosin α-1
Tirzepatide
1. Reconstitution
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
2× weekly, e.g. Monday + Thursday.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Needle
27–31G, 4–8 mm insulin syringe.
Pen-supplied. Research vial: 27–31G insulin syringe.